An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with <i>In Vivo</i> Efficacy against Drug-Resistant Gram-Negative Infections-Reference-Cited by-同舟云学术

An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with In Vivo Efficacy against Drug-Resistant Gram-Negative Infections

Published:2022-08-10 Issue:8 Volume:8 Page:1145-1158
ISSN:2374-7943
Container-title:ACS Central Science
language:en
Short-container-title:ACS Cent. Sci.

Author:

Parker Erica N.¹^ORCID,Cain Brett N.¹,Hajian Behnoush²,Ulrich Rebecca J.¹^ORCID,Geddes Emily J.¹,Barkho Sulyman²,Lee Hyang Yeon¹,Williams John D.³,Raynor Malik³,Caridha Diana³,Zaino Angela²,Shekhar Mrinal²,Muñoz Kristen A.¹,Rzasa Kara M.²,Temple Emily R.²,Hunt Diana²⁴,Jin Xiannu³,Vuong Chau³,Pannone Kristina³,Kelly Aya M.¹,Mulligan Michael P.¹,Lee Katie K.²,Lau Gee W.⁵^ORCID,Hung Deborah T.²⁴^ORCID,Hergenrother Paul J.¹^ORCID

Affiliation:

1. Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States

2. Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States

3. Walter Reed Army Institute of Research, Silver Spring, Maryland 20910 United States

4. Department of Molecular Biology and Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts 02115, United States

5. Department of Pathobiology, College of Veterinary Medicine, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States

Funder

National Institute of Allergy and Infectious Diseases

National Institute of General Medical Sciences

University of Illinois

National Science Foundation

Military Infectious Disease Research Program

Biomedical Advanced Research and Development Authority

Publisher

American Chemical Society (ACS)

Subject

General Chemical Engineering,General Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acscentsci.2c00598

Reference53 articles.

1. Safety and Efficacy of Daptomycin as First-Line Treatment for Complicated Skin and Soft Tissue Infections in Elderly Patients: An Open-Label, Multicentre, Randomized Phase IIIb Trial

2. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial

3. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial

4. WHO Antibacterial products in clinical development for priority pathogens. https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/antibacterial-products-in-clinical-development-for-priority-pathogens (accessed June 13, 2022).

5. Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N-acyl-4-arylaminopiperidines: Design and synthesis of a potential antimicrobial scaffold;Bioorganic & Medicinal Chemistry Letters;2024-11

2. Evaluation of antifungal spectrum of Cupferron against Candida albicans;Microbial Pathogenesis;2024-09

3. Unveiling the role of macranthoin G in the traditional anti-infective properties of Launaea nudicaulis;South African Journal of Botany;2024-09

4. Design and synthesis of a library of C8-substituted sulfamidoadenosines to probe bacterial permeability;Bioorganic & Medicinal Chemistry Letters;2024-09

5. Molecular Mechanism of Ciprofloxacin Translocation Through the Major Diffusion Channels of the ESKAPE Pathogens Klebsiella pneumoniae and Enterobacter cloacae;The Journal of Physical Chemistry B;2024-08-24